conv.

← The whole story
Business
Novartis licenses BoomRay radioligand therapy asset for $900M

Novartis and BoomRay sign $900M radioligand therapy license agreement

1 Sep 22 · 1d ago · 5 articles · 1 source · development 1 of 2

China-based clinical-stage biotech company BoomRay Pharmaceuticals and Novartis announced an exclusive worldwide license deal for an undisclosed preclinical radioligand therapy asset. The agreement includes an upfront payment plus potential development, regulatory, and sales milestone payments, along with possible royalties on future global net sales.

Novartis and BoomRay sign $900M radioligand therapy license agreement
Yahoo Finance

“This agreement marks a significant milestone for BoomRay and is a strong validation of our discovery and development capabilities.”

Bo Shan

BoomRay Pharmaceuticals Clinical-stage biotech companyNovartis Global pharmaceutical companyBo Shan BoomRay CEOShiva Malek Novartis oncology, biomedical research global head

The whole story articles the bright band is this development · numbered dots are the others · click one to jump

Peak 5 pieces in one hour at Sep 22, 12 PM; 6 pieces over 38 hours (6 articles) Sep 22, 12 PM — 5 pieces · 5 articles — Google News 5Sep 22, 1 PM — quietSep 22, 2 PM — quietSep 22, 3 PM — quietSep 22, 4 PM — quietSep 22, 5 PM — quietSep 22, 6 PM — quietSep 22, 7 PM — quietSep 22, 8 PM — quietSep 22, 9 PM — quietSep 22, 10 PM — quietSep 22, 11 PM — quietYesterday, 12 AM — quietYesterday, 1 AM — quietYesterday, 2 AM — quietYesterday, 3 AM — quietYesterday, 4 AM — quietYesterday, 5 AM — 1 piece · 1 article — Newswires 1Yesterday, 6 AM — quietYesterday, 7 AM — quietYesterday, 8 AM — quietYesterday, 9 AM — quietYesterday, 10 AM — quietYesterday, 11 AM — quietYesterday, 12 PM — quietYesterday, 1 PM — quietYesterday, 2 PM — quietYesterday, 3 PM — quietYesterday, 4 PM — quietYesterday, 5 PM — quietYesterday, 6 PM — quietYesterday, 7 PM — quietYesterday, 8 PM — quietYesterday, 9 PM — quietYesterday, 10 PM — quietYesterday, 11 PM — quietToday, 12 AM — quietToday, 1 AM — quiet 12
1Novartis and BoomRay sign $900M…2Deal details highlight Novartis's…
4 PMyesterday8 AM4 PMnow · 2:58 AM ET

What was reported 3 claims about this development

  1. 4 outlets Novartis licenses BoomRay radioligand asset for $900M

    first by European Biotechnology Magazine, 1d ago · also AllSci, Pharmaceutical Executive, FirstWord Pharma

    3 more headlines
  2. 1 outlet BoomRay and Novartis Pharma sign $900m deal for radioligand therapy

    first by Yahoo Finance, 20h ago

  3. 1 outlet Novartis secures new radioligand in $900M deal as competition strengthens

    first by Fierce Biotech, 1d ago

All 2 developments of Novartis licenses BoomRay radioligand therapy asset for… →

Google NewsNewswires